New Zealand markets open in 2 hours 5 minutes

LLY Jan 2025 400.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.25000.0000 (0.00%)
As of 01:40PM EDT. Market open.
Full screen
Previous close2.2500
Open2.3900
Bid2.0500
Ask4.7500
Strike400.00
Expiry date2025-01-17
Day's range2.2500 - 2.4500
Contract rangeN/A
Volume10
Open interest1.77k
  • Yahoo Finance Video

    Eli Lilly's weight loss drug could help sleep apnea patients

    Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepbound. The trial revealed that the drug helped patients with sleep apnea, a condition characterized by irregular breathing during sleep. The company is now moving to apply for an expanded label from the US Food and Drug Administration (FDA). If approved, it would allow Zepbound to be prescribed and used for the treatment of sleep apnea, in addition to its current weight loss use. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Angel Smith

  • Investor's Business Daily

    Stocks Waver After Fed Data; Tesla Pares Losses As Musk Faces Shareholder Vote

    Stocks were mixed ahead of Fed data Wednesday. ASML sold off after earnings. Nvidia remained in a base.

  • Investor's Business Daily

    Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

    Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.